Phase 1 · NCT06808802
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
A Phase 1, Open-label, Single-arm Study to Investigate the Effect of Retatrutide on Metoprolol Pharmacokinetics in Healthy Participants
CompletedVerified
Trial registry record
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
- ClinicalTrials.gov ID
- NCT06808802
- Indication
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 30
- Status
- Completed
- Interventions
- Drug: Retatrutide; Drug: Metoprolol
- Comparator
- Not reported
- Eligible ages
- 21 Years – 65 Years
- Locations
- 1 site · Singapore
- Study start
- 3 Feb 2025
- Primary completion
- 15 Apr 2025
- Study completion
- 15 Apr 2025
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 5 Jun 2025
Endpoints
Primary
Pharmacokinetics (PK): Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol; Pharmacokinetics (PK): AUC (0-∞) of Metoprolol with Retatrutide; PK: Maximum Concentration (Cmax) of Metoprolol; PK: Cmax of Metoprolol with Retatrutide
Secondary
Number of Participants with an Incidence of Treatment Emergent Adverse Events TEAEs (TEAEs)